SynthesisDrug safety2017
Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.
Synthesis in Drug safety, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Antibiotics for secondary prevention of coronary heart disease.The Cochrane database of systematic reviews · 2021Pooled it
- Adverse events in people taking macrolide antibiotics versus placebo for any indication.The Cochrane database of systematic reviews · 2019Pooled it
- Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides.Antimicrobial agents and chemotherapy · 2018Pooled it
- Article
- Impact of pulmonary infection and antibiotic use on recurrent myocardial infarction in patients with myocardial infarction.Scientific reports · 2025Article
- Empirical antibiotic treatment for community-acquired pneumonia and accuracy for Legionella pneumophila, Mycoplasma pneumoniae, and Clamydophila pneumoniae: a descriptive cross-sectional study of adult patients in the emergency department.BMC infectious diseases · 2023Article
- The potential links between human gut microbiota and cardiovascular health and disease - is there a gut-cardiovascular axis?Frontiers in gastroenterology (Lausanne, Switzerland) · 2023Review
- Administration of macrolide antibiotics increases cardiovascular risk.Frontiers in cardiovascular medicine · 2023Article
- The Gut Microbiota and Vascular Aging: A State-of-the-Art and Systematic Review of the Literature.Journal of clinical medicine · 2022Review
- Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis.ERJ open research · 2022Article
- Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials.BMC medicine · 2021Review
- [Safety in the selection of oral antibiotic treatment in community infections, beyond COVID-19].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Review
- Triggering of cardiovascular disease by infection type: The Atherosclerosis Risk in Communities study (ARIC).International journal of cardiology · 2021Article
- Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study.BMJ (Clinical research ed.) · 2020Article
- Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality: Prospective Cohort Study.Circulation research · 2020Article
- Duration and life-stage of antibiotic use and risk of cardiovascular events in women.European heart journal · 2019Article
- [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Review
- Hot topics and current controversies in community-acquired pneumonia.Breathe (Sheffield, England) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular events as a result of macrolide use.
methodsSeveral electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ≥18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration's tool. The body of evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines.
resultsObservational studies were found to have a short-term risk of cardiovascular outcomes including cardiovascular mortality, myocardial infarction, and arrhythmia associated with macrolides but no risk was found in randomized controlled trials. However, no association for long-term risk (ranging from >30 days to >3 years) was observed in observational studies or randomized controlled trials. LIMITATIONS: The included studies reported different units of denominators for absolute risk and used different outcome definitions, which might increase the heterogeneity.
conclusionsMore studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.